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Abstract
Background
Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple scle-
rosis (RMS) revealed a decrease in placebo annualized relapse rates (ARR) over the past
two decades. Furthermore, regression to the mean effects were observed in ARR and MRI
lesion counts. It is unclear whether disease progression measured by the expanded disabil-
ity status scale (EDSS) exhibits similar features.
Methods
A systematic review of RCTs in RMS was conducted extracting data on EDSS and baseline
characteristics. The logarithmic odds of disease progression were modelled to investigate
time trends. Random-effects models were used to account for between-study variability; all
investigated models included trial duration as a predictor to correct for unequal study dura-
tions. Meta-regressions were conducted to assess the prognostic value of a number of
study-level baseline variables.
Results
The systematic literature search identified 39 studies, including a total of 19,714 patients.
The proportion of patients in placebo controls experiencing a disease progression
decreased over the years (p<0.001). Meta-regression identified associated covariates
including the size of the study and its duration that in part explained the time trend. Progres-
sion probabilities tended to be lower in the second year of a study compared to the first year
with a reduction of 28% in progression odds from year 1 to year 2 (p = 0.017).
Conclusion
EDSS disease progression exhibits similar behaviour over time as the ARR and point to
changes in trial characteristics over the years. This needs to be considered in comparisons
between historical and recent trials.
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Introduction
Recent systematic reviews of placebo groups in randomised controlled trials (RCTs) in relaps-
ing multiple sclerosis (RMS), i.e. relapsing remitting and relapsing secondary progressive mul-
tiple sclerosis, suggest a decrease in annualized relapse rates (ARRs) over calendar time [1–3]
as well as a decrease in relapse rates over the course of the study [4]. These changes appear to
relate to the changing eligibility criteria and populations entering trials and regression to the
mean effects [3]. Pre-trial ARR and mean baseline age were independently identified as predic-
tors for on-trial ARR in a smaller number of phase III trials with at least 18 months follow-up
by Stellmann et al. [5]. Recently regression to the mean in MRI lesion counts was identified
and quantified in a systematic review and meta-analysis [6].
Disability outcomes in multiple sclerosis (MS) are a key component that regulators have
identified as the principal target for an increasing range of therapies targeting the underlying
disease process [7]. The commonly used method of disability measurement in trials is the
extended disability status scale (EDSS) [8].
In this paper we aim to investigate whether a decrease in placebo ARRs observed in ran-
domized controlled trials in RMS is also present in EDSS progression and, if so, whether it can
also be explained by changes in patient populations and study design characteristics. Further-
more, we will assess placebo controls of RCTs for regression to the mean effects in EDSS
progression.
Methods
Systematic literature search
A recently conducted systematic literature search for placebo controlled randomised trials in
RMS [3] was updated by searching PubMed with the aim of identifying placebo-controlled, dou-
ble-blind RCTs in MS where all or some of the patients had a relapsing form of the disease and
that reported data on pre-trial and on-trial ARR as well as on pre-trial and on-trial EDSS. To
update the previous systematic review we searched for articles published from 2011 onwards
with the search terms “multiple sclerosis”, “relapse rate” and “placebo”. All abstracts were inde-
pendently screened by two reviewers. The search was performed on February 20th, 2015. If one
reviewer suggested that the full paper should be examined after reading the abstract, the full
paper was considered. For a trial to be included in this systematic review it had to be randomised,
double blind, and placebo-controlled, with at least some of the trial participants having RMS and
results for participants with RMS having been reported seperately. Trials had to assess the efficacy
of disease modifying drugs (i.e. not assessing symptomatic therapies), and report data on both
clinical relapses and EDSS. We excluded cross-over trials and studies where patients in the con-
trol group received a form of active treatment (add-on therapy).
Data extraction
The following data were extracted by one reviewer and verified by another:
• publication date, treatment groups and corresponding numbers of patients, and duration of
follow-up,
• the proportion of patients experiencing a worsening in EDSS,
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• the ordinates at years 1 and 2 of Kaplan-Meier curves of confirmed EDSS progression, or
equivalent tabulated data.
Data analysis
For the purpose of all analyses of temporal trends, the year and month of publication and the
study durations were used. EDSS progression was analyzed based on the logarithmic odds (log-
odds) of disease progression; these result as log p^
1p^
 
, where p^ is the fraction of progressing
patients. Corresponding standard errors are calculated based on a binomial model as
s^ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
k
þ 1
Nk
q
, where N is the total number of patients, out of which k have progressed. We
assessed publication bias using funnel plots and Egger’s tests. In the meta-regression analyses
we utilized linear regression methods, accounting for the standard errors of the individual stud-
ies. Random-effects models were used in order to account for potential between-study variabil-
ity, and all investigated models included trial duration as a predictor in order to correct for
unequal study durations [9]. Between-study heterogeneity τ2 was estimated using the Mandel-
Paule method [10] which is reported with the p-values of the chi-square test of heterogeneity.
Furthermore, the I2 measure for between-trial heterogeneity is reported with a 95% conﬁdence
interval. For the multiple regression, we used the Bayesian information criterion (BIC) to deter-
mine the best-ﬁtting model among all possible subsets of predictors [11]. For the predicted
means 95% conﬁdence intervals were calculated. We used random-effects meta-analysis on the
log odds scale to investigate the probability of EDSS progression during ﬁrst and second year of
a study. EDSS progression probabilities for years 1 and 2 were calculated from the cumulative
probabilities reported in the studies. In estimating the standard errors of the log risk ratios we
neglected correlations between the risk estimates (the empirical fractions of patients are posi-
tively correlated, and so we err on the conservative side here, overestimating the uncertainty in
differences or ratios leading to wider conﬁdence intervals). We used the R software (www.r-
project.org) in conjunction with the metafor package (http://cran.r-project.org/package =
metafor) to perform meta-analyses and meta-regressions.
Results
Studies identified and clinical features of the placebo groups
The systematic literature search identified 39 studies, including a total of 19,714 patients, of
which 6,947 received placebo. The cumulative observation time amounts to 31,368 patient-
years, with a contribution of 11,163 patient-years from placebo treated patients. The study
selection process is illustrated in the flow chart in S1 Fig. In the placebo controls of the identi-
fied trials the medians of the mean baseline EDSS and pre-trial ARR were 2.7 (range 1.9 to 5.1)
and 1.4 (range 0.9 to 2.1), respectively. During the trials the placebo ARR were somewhat lower
with a median of 0.8 (range 0.22 to 1.8). The study characteristics are summarized in Table 1.
Disease progression can be defined in a number of ways, of the 39 included studies, disability
worsening of one point or more on the EDSS scale was used in 34 (87%) and progression con-
firmation of 3 months or more was used in 23 (59%).
Decreasing placebo EDSS progression rates over the past two decades
Fig 1 shows the fractions of progressing patients as reported in different studies’ placebo groups
over the years. The chances of progression of course also depend on the trial duration
(“shorter” and “longer” studies are also indicated by different symbols), but even after
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Table 1. Baseline characteristics of all randomised patients and the patients in the placebo groups in
the 39 randomised, controlled trials included in this systematic review. N denotes the number of treat-
ment arms for which the corresponding figures could be extracted.
Placebo groups All treatment groups
N Median (range) N Median (range)
number of patients 39 99 (9–556) 97 123 (9–943)
study duration (years) 39 2.00 (0.46–5.00) 97 1.85 (0.46–5.00)
mean pre-trial EDSS 36 2.68 (1.94–5.05) 91 2.69 (1.86–6.05)
mean on-trial EDSS 23 2.88 (1.88–5.59) 55 2.79 (1.87–6.50)
EDSS progressing proportion 39 0.23 (0.04–0.50) 97 0.18 (0.04–0.76)
mean pre-trial ARR 32 1.40 (0.87–2.10) 80 1.37 (0.75–2.10)
mean on-trial ARR 39 0.81 (0.22–1.80) 97 0.54 (0.14–1.80)
doi:10.1371/journal.pone.0137052.t001
Fig 1. The fractions of patients with progressing EDSS status over the years. The chances of progression also depend on the study duration (you can
see that shorter studies have smaller fractions) but even after accounting for the duration, the decreasing trend remains statistically significant (p<0.0001).
The red line shows the estimated regression line for a trial duration of 1 year.
doi:10.1371/journal.pone.0137052.g001
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accounting for the individual follow-up times, the regression analysis indicates a statistically signif-
icant effect of the publication year with the odds for disease progression decreasing by 31% (95%
CI [17%, 42%]) within a decade (p<0.001; between-trial heterogeneity τ2 = 0.15 (95% CI [0.07,
0.31]), I2 = 79.8% (95% CI [66.3, 89.2]), p<0.001). The funnel plots (not shown) and Egger’s tests
(p = 0.22 for short studies and p = 0.45 for long studies) did not suggest any publication bias.
Predictors of EDSS disease progression
Table 2 shows the results from univariate regression analyses using the remaining covariates
(excluding the publication year). These are the number of placebo patients, study length,
Oxford Quality Scale score, use of confirmed progression, the number eligibility criteria as well
as the number of words used to describe them, mean baseline age in years, mean baseline
EDSS, and baseline ARR, mean baseline MS duration in years, follow-up duration in years, and
number of treatment arms. For each of the predictors investigated, the odds ratio, which is the
multiplicative change in odds for EDSS progression for every unit increase in the predictor, is
shown along with its 95% confidence interval and p-value. Note that all investigated models
included follow-up time as a covariate. For each analysis, the value of τ2, the random effect
accounting for between-study heterogeneity is shown as well, along with the relative reduction
in τ2 compared to the model that only uses follow-up time as a predictor. With larger numbers
of placebo patients the progression probability decreases (OR 0.998 per patient, 95% CI [0.998,
0.999], p = 0.0004). As would have been expected, the progression probability increases with
Table 2. Results of univariable andmultivariable regression aiming at explaining the probability of EDSS progression. Regression coefficients
relate to the logarithmic odds of progression. τ2 denotes the unexplained between-study heterogeneity, and the reduction percentages relate to the model
including only follow-up duration as a predictor (which is also included in all univariable models). The multivariable model was selected based on the Bayesian
information criterion (BIC).
Univariable Multivariable
variable odds
ratio
95% CI p-value τ2 (red. %) odds
ratio
95% CI p-value τ2 (red.
%)1
number of placebo patients 0.99839 0.99750, 0.99928 0.00040 0.405
(32.2)
0.99744 0.99607,
0.99880
0.00024 0.366
(44.5)
long study (>1 year) 1.852 1.087, 3.155 0.023 0.457
(13.7)
1.877 1.156, 3.157 0.018 0.366
(44.5)
Oxford Quality Scale score 0.777 0.602, 1.003 0.053 0.468 (9.4)
conﬁrmed progression (yes) 0.709 0.475, 1.058 0.092 0.475 (6.4) 1.369 0.799, 2.347 0.25 0.366
(44.5)
mean baseline age (years) 0.9783 0.9192, 1.0412 0.49 0.482 (3.9)
eligibility criteria: number of
words
0.999042 0.997634,
1.000452
0.18 0.482 (2.8)
mean baseline EDSS 1.0383 0.7749, 1.3913 0.80 0.485 (2.0) 0.822 0.619, 1.092 0.18 0.366
(44.5)
mean baseline MS duration
(years)
0.9791 0.8912, 1.0756 0.66 0.490 (0.6)
followup duration (years) 1.614 1.312, 1.984 0.0000058 0.492 (0.0) 1.171 0.889, 1.543 0.26 0.366
(44.5)
eligibility criteria: number 0.99475 0.98193, 1.00774 0.43 0.495 (-1.4)
number of treatment arms 0.788 0.577, 1.078 0.14 0.498 (-2.4)
baseline ARR 1.290 0.663, 2.511 0.45 0.528
(-15.2)
0.883 0.477, 1.634 0.69 0.326
(56.1)
1 heterogeneity is the same for all variables in the multivariable model.
doi:10.1371/journal.pone.0137052.t002
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the length of the study (OR 1.852 for studies longer than 1 year vs. studies up to 1 year, 95% CI
[1.09, 3.16], p = 0.023 for< = 1 vs.>1 year; OR 1.61 per year, 95% CI [1.31, 1.98], p<0.0001
for linear trend).
The model selection result is also shown in Table 2. The variables included in the final
model relate to study size (number of placebo patients: OR 0.997, 95% CI [0.996; 0.999],
p<0.001), study duration (follow-up duration in years: OR 1.17 per year, 95% CI [0.889, 1.54],
p = 0.26; study longer 1 year: OR 1.88, 95% CI (1.16, 3.16), p = 0.018) and baseline disease sta-
tus (baseline ARR: OR 0.883, 95% CI [0.477, 1.63], p = 0.69; mean baseline EDSS: OR 0.822 per
point on EDSS scale, 95% CI [0.619, 1.09], p = 0.18) and confirmation of disease progression
(OR 1.37 for confirmation vs. without confirmation, 95% CI [0.799, 2.35], p = 0.25).
Decreasing EDSS disease progression over follow-up time
Fig 2 illustrates the probabilities of progression during the first and second years of follow-up
for the 13 studies where relevant data could be extracted. Overall progression probabilities tend
to be lower in the second year, with the exception of two small studies from the 1990’s. The
combined odds ratio comparing the progression probabilities from year 2 to year 1 is 0.72
(95% CI [0.56; 0.93], p = 0.017; between-trial heterogeneity τ2 = 0.096 (95% CI [0.017; 0.40], I2
= 57.7% (95% CI [19.2; 85.1]), p = 0.0028) which translates to a reduction of 28% in progres-
sion odds from year 1 to year 2. In the S2 Fig, a forest plot of the progression odds ratios is
given providing a more conventional summary of the effects. Looking at combined progression
probabilities from random-effects meta-analyses, chances are 16.9% during the first year, and
13.1% during the second year. These studies used confirmed disease progression as the end-
point. When considering only the eight most recent studies published during the last decade,
the numbers change slightly to 16.0% and 11.2% during first and second year, respectively.
Discussion
For the key clinical outcome measure of disease progression in MS [7], this study has con-
firmed that in relapsing MS trial placebo groups the rates of disease progression reduce with
the more recent publication year of the study and between the first and second year of the
study. These findings further question the appropriateness of comparing relative risk reduc-
tions of drug to placebo for newer to older drugs in an attempt to argue higher potency of the
newer agents. Recently a review including more than 1,000 meta-analyses from the Cochrane
Library revealed a decrease in publication bias over time [12], but we feel this is unlikely to be
the explanation of our findings as publication bias is usually associated with the treatment
effect and we only considered the outcome of the control group.
Despite meta-regressions with this number of studies having a limited power, we found that
increasing study size and decreasing length of the study were significant in reducing rates of
disease progression seen in studies with later publication year. Study size has already been
shown to be highly correlated with publication year for ARR [3]. However, a reduced ARR
with later publication date was associated with a shorter study length whereas an increased rate
of EDSS progression rate was associated with increased study length. For ARR this is because
the earlier studies were longer and the study populations of the earlier trials had higher disease
activity whereas for disease progression the increase with length of study is due to the way in
which cumulative progression is calculated, i.e. those who progress in the first year are added
to those who progress subsequently. Thus both these features may well be simply confounding
factors and, unlike in the case of ARR, we did not find any other subject or study design fea-
tures explaining this trend [3]. With the advance in diagnostics (e.g. MRI) and therapies in
RMS over the past two decades, the eligibility criteria for RMS trials changed considerably over
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the years. In our analyses we captured the number of eligibility criteria and the number of
words used to describe these. We did not carry out any detailed analyses of the eligibility crite-
ria, which could be considered a limitation of our analysis and could be the subject of future
research.
We have also found that the rates of disease progression reduce from the first to the second
year implying as with ARR rates there is a regression to the mean effect. This is seen within the
context of RMS where subjects are chosen to enter studies after a series of relapses which then
Fig 2. The fractions of patients with progressing EDSS in the first and second year of study, for the 13 studies of at least 2 years duration, and
where the data was provided. Connecting lines indicate the rates for the two subsequent years, line widths are proportional to study sizes (numbers of
patientsN). The weighted average (weighted by the inverse variances on the log odds scale) decreases from 16.9% to 13.1% from first to second year.
[16.0% to 11.2% for the 8 most recent post-2000 studies].
doi:10.1371/journal.pone.0137052.g002
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can settle down spontaneously [4]. However, as with the time-to-first relapse endpoint an alter-
native explanation for the apparent time-dependence in the time-to-disease progression data
could be between-patient heterogeneity [13]. The observed trend warrants further investigation
in the form of analyses of individual patient data (IPD). IPD meta-analyses would allow the
investigation of both study-level and patient-level characteristics.
Although correlations on a patient level between MRI outcomes, relapse and EDSS progres-
sion are small [14,15], known as the clinico-radiological paradox [16], the trends over time on
a population level are quite similar in these three measures. Given the similar relationship what
we may be seeing is the impact of the early phase of MS relapses and MRI activity on the dis-
ability score. The EDSS has acknowledged limitations [17–19] and levels of disability especially
in early MS are very variable [20] as relapses are known to bias the assessment of disability.
Here disability progression was defined predominantly using a one point increase in the EDSS
combined with 3 months confirmation. Time to 3 months confirmed disability progression is
known to be more susceptible to the impact of relapses than measures that use a longer period
to confirm a change in disability [7,19]. In summary, EDSS disease progression as used here
exhibits similar behaviour over time as the ARR and point to changes in trial characteristics
over the years, questioning comparisons between historical and recent trials.
In our investigations we have paid careful attention to modelling potential between-study
heterogeneity by using the Mandel-Paule estimator [10]. In the light of recent findings suggest-
ing that between-study heterogeneity is often underestimated, in particular in meta-analyses
with small numbers of trials, [21] this appears to be appropriate. At least in the main analyses
presented here, however, the number of trials was sufficiently large to estimate the between-
study variation reliably.
Investigations into the prediction of treatment response are an ongoing effort with some
promising approaches including the modified Rio score [22,23]. These might allow a stratifica-
tion of trial populations in the future resulting ultimately in a better understanding of which
patients benefit most from certain therapies.
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